Following the passage of continuing resolutions (CR) by the US Senate and the House of Representatives this week, lab test reimbursement cuts and price reporting requirements called for under the Protecting Access to Medicare Act (PAMA) are likely to be delayed one year.

In terms of the pharmaceutical macro-political environment, the biomedical industry policies such as medical insurance cost control and target quantity procurement, are gradually implementing.

On February 21, the Notification on Regulating the Adjustment of Some Medical Service Prices, which included 16 assisted reproductive technologies such as artificial insemination and embryo transfer into Beijing medical insurance, was issued.